Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension | NEJM
Original Article from The New England Journal of Medicine — Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
Related Articles
A Modular Communicative Leadless Pacing–Defibrillator System | NEJM
The subcutaneous implantable cardioverter–defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the subcutaneous ICD cannot provide bradycardia an…
To Preround or Not to Preround | NEJM
This feature about an attending preparing for her upcoming week of service offers a case vignette accompanied by two essays, one supporting visiting patients early…
Olezarsen for Hypertriglyceridemia | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Olezarsen for Hypertriglyceridemia
Perioperative Nivolumab in Resectable Lung Cancer | NEJM
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Early Diagnosis and Treatment of COPD and Asthma — A Randomized, Controlled Trial | NEJM
Many persons with chronic obstructive pulmonary disease (COPD) or asthma have not received a diagnosis, so their respiratory symptoms remain largely untreated. We used a…
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk | NEJM
Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (A…
Implications of Race Adjustment in Lung-Function Equations | NEJM
Adjustment for race is discouraged in lung-function testing, but the implications of adopting race-neutral equations have not been comprehensively quantified. We obtained longitudinal data from…
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation | NEJM
Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation, has…
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We…
Pulmonary Arterial Hypertension | NEJM
Without effective treatment, pulmonary arterial hypertension results in high morbidity and mortality. This review discusses the pathogenesis of the disorder, the thorough clinical evaluation requir…
